BusinessCORRECTING and REPLACING -- Improved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective StudyBy Nasdaq OMXJan 24, 2017, 6:04 PM UTC
BusinessImproved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective StudyBy Nasdaq OMXJan 10, 2017, 4:33 PM UTC
BusinessEntia Biosciences, Inc. (OTCQB: ERGO) Receives Notification of the Grant of European Patent it has Exclusively Licensed for Identifying the Ergothioneine Transporter and its Therapeutic UsesBy Nasdaq OMXNov 2, 2016, 7:20 PM UTC
BusinessEntia Biosciences, Inc. (OTCQB: ERGO) to Present Results of Chronic Kidney Disease Medical Food Clinical Study at American Society of Nephrology / Kidney Week 2016 Annual MeetingBy Nasdaq OMXOct 6, 2016, 4:52 PM UTC
BusinessPreliminary clinical results for Entia Biosciences, Inc.’s new, proprietary ErgoD2® medical food show an average increase in kidney filtration rate of approximately 10% for over 75% of test subjects, after only three monthsBy Nasdaq OMXSep 26, 2016, 12:30 PM UTC
BusinessFilament BioSolutions Announces Strategic Partnership With Ajinomoto to Develop a Portfolio of Evidence-Based Medical FoodsBy Nasdaq OMXJan 11, 2016, 2:33 PM UTC
